{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:40:04Z","timestamp":1773949204299,"version":"3.50.1"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Health commission of Hubei Province scientific research project","award":["WJ2019H080"],"award-info":[{"award-number":["WJ2019H080"]}]},{"name":"Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2020-PT320-004"],"award-info":[{"award-number":["2020-PT320-004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prostate cancer (PCa) is one of the most commonly diagnosed human cancers in males. Nearly 191,930 new cases and 33,330 new deaths of PCa are estimated in 2020. Androgen and androgen receptor pathways played essential roles in the pathogenesis of PCa. Androgen depletion therapy is the most used therapies for primary PCa patients. However, due to the high relapse and mortality of PCa, developing novel noninvasive therapies have become the focus of research. Melatonin is an indole-like neurohormone mainly produced in the human pineal gland with a prominent anti-oxidant property. The anti-tumor ability of melatonin has been substantially confirmed and several related articles have also reported the inhibitory effect of melatonin on PCa, while reviews of this inhibitory effect of melatonin on PCa in recent 10\u00a0years are absent. Therefore, we systematically discuss the relationship between melatonin disruption and the risk of PCa, the mechanism of how melatonin inhibited PCa, and the synergistic benefits of melatonin and other drugs to summarize current understandings about the function of melatonin in suppressing human prostate cancer. We also raise several unsolved issues that need to be resolved to translate currently non-clinical trials of melatonin\u00a0for\u00a0clinic use. We hope this literature review could provide a solid theoretical basis for the future utilization of melatonin in preventing, diagnosing and treating human prostate cancer.<\/jats:p>","DOI":"10.1186\/s12964-021-00723-0","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T13:02:51Z","timestamp":1615813371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The inhibitory effect of melatonin on human prostate cancer"],"prefix":"10.1186","volume":"19","author":[{"given":"Dexin","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingao","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenfang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongzu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1377-9685","authenticated-orcid":false,"given":"Yu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiyu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"723_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"723_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"723_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"723_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"723_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.urolonc.2015.01.008","volume":"33","author":"DJ De Maeseneer","year":"2015","unstructured":"De Maeseneer DJ, Van Praet C, Lumen N, Rottey S. Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations. Urol Oncol. 2015;33:310\u201321.","journal-title":"Urol Oncol"},{"key":"723_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/cancers12010051","volume":"12","author":"S Saranyutanon","year":"2019","unstructured":"Saranyutanon S, Srivastava SK, Pai S, Singh S, Singh AP. Therapies targeted to androgen receptor signaling axis in prostate cancer: progress, challenges, and hope. Cancers (Basel). 2019;12:51.","journal-title":"Cancers (Basel)"},{"key":"723_CR7","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","volume":"71","author":"C Cai","year":"2011","unstructured":"Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71:6503\u201313.","journal-title":"Cancer Res"},{"key":"723_CR8","doi-asserted-by":"publisher","first-page":"6802","DOI":"10.1158\/1078-0432.CCR-17-1034","volume":"23","author":"H Beltran","year":"2017","unstructured":"Beltran H, Wyatt AW, Chedgy EC, Donoghue A, Annala M, Warner EW, Beja K, Sigouros M, Mo F, Fazli L, et al. Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy. Clin Cancer Res. 2017;23:6802\u201311.","journal-title":"Clin Cancer Res"},{"key":"723_CR9","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.3390\/ijms20102587","volume":"20","author":"SK Wong","year":"2019","unstructured":"Wong SK, Mohamad NV, Giaze TR, Chin KY, Mohamed N, Ima-Nirwana S. Prostate cancer and bone metastases: the underlying mechanisms. Int J Mol Sci. 2019;20:2587.","journal-title":"Int J Mol Sci"},{"key":"723_CR10","doi-asserted-by":"publisher","first-page":"e12636","DOI":"10.1111\/jpi.12636","volume":"68","author":"CE Carvalho-Sousa","year":"2020","unstructured":"Carvalho-Sousa CE, Pereira EP, Kinker GS, Veras M, Ferreira ZS, Barbosa-Nunes FP, Martins JO, Saldiva PHN, Reiter RJ, Fernandes PA, et al. Immune-pineal axis protects rat lungs exposed to polluted air. J Pineal Res. 2020;68:e12636.","journal-title":"J Pineal Res"},{"key":"723_CR11","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00018-014-1579-2","volume":"71","author":"D Acuna-Castroviejo","year":"2014","unstructured":"Acuna-Castroviejo D, Escames G, Venegas C, Diaz-Casado ME, Lima-Cabello E, Lopez LC, Rosales-Corral S, Tan DX, Reiter RJ. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014;71:2997\u20133025.","journal-title":"Cell Mol Life Sci"},{"key":"723_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.exer.2016.11.019","volume":"154","author":"HA Alkozi","year":"2017","unstructured":"Alkozi HA, Wang X, Perez de Lara MJ, Pintor J. Presence of melanopsin in human crystalline lens epithelial cells and its role in melatonin synthesis. Exp Eye Res. 2017;154:168\u201376.","journal-title":"Exp Eye Res"},{"key":"723_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.exger.2009.02.002","volume":"44","author":"M Sanchez-Hidalgo","year":"2009","unstructured":"Sanchez-Hidalgo M, de la Lastra CA, Carrascosa-Salmoral MP, Naranjo MC, Gomez-Corvera A, Caballero B, Guerrero JM. Age-related changes in melatonin synthesis in rat extrapineal tissues. Exp Gerontol. 2009;44:328\u201334.","journal-title":"Exp Gerontol"},{"key":"723_CR14","doi-asserted-by":"publisher","first-page":"e0120195","DOI":"10.1371\/journal.pone.0120195","volume":"10","author":"F Soderquist","year":"2015","unstructured":"Soderquist F, Hellstrom PM, Cunningham JL. Human gastroenteropancreatic expression of melatonin and its receptors MT1 and MT2. PLoS ONE. 2015;10:e0120195.","journal-title":"PLoS ONE"},{"key":"723_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1600-079X.2011.00856.x","volume":"51","author":"JH Stehle","year":"2011","unstructured":"Stehle JH, Saade A, Rawashdeh O, Ackermann K, Jilg A, Sebesteny T, Maronde E. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res. 2011;51:17\u201343.","journal-title":"J Pineal Res"},{"key":"723_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1210\/edrv-12-2-151","volume":"12","author":"RJ Reiter","year":"1991","unstructured":"Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev. 1991;12:151\u201380.","journal-title":"Endocr Rev"},{"key":"723_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2174\/157016109788340749","volume":"7","author":"A Dominguez-Rodriguez","year":"2009","unstructured":"Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Clinical aspects of melatonin in the acute coronary syndrome. Curr Vasc Pharmacol. 2009;7:367\u201373.","journal-title":"Curr Vasc Pharmacol"},{"key":"723_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11154-009-9125-5","volume":"10","author":"A Chattoraj","year":"2009","unstructured":"Chattoraj A, Liu T, Zhang LS, Huang Z, Borjigin J. Melatonin formation in mammals: in vivo perspectives. Rev Endocr Metab Disord. 2009;10:237\u201343.","journal-title":"Rev Endocr Metab Disord"},{"key":"723_CR19","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3390\/molecules23061308","volume":"23","author":"A Giudice","year":"2018","unstructured":"Giudice A, Crispo A, Grimaldi M, Polo A, Bimonte S, Capunzo M, Amore A, D\u2019Arena G, Cerino P, Budillon A, et al. The effect of light exposure at night (LAN) on carcinogenesis via decreased nocturnal melatonin synthesis. Molecules. 2018;23:1308.","journal-title":"Molecules"},{"key":"723_CR20","doi-asserted-by":"publisher","first-page":"e12614","DOI":"10.1111\/jpi.12614","volume":"68","author":"M Schilperoort","year":"2020","unstructured":"Schilperoort M, van den Berg R, Bosmans LA, van Os BW, Dolle MET, Smits NAM, Guichelaar T, van Baarle D, Koemans L, Berbee JFP, et al. Disruption of circadian rhythm by alternating light-dark cycles aggravates atherosclerosis development in APOE*3-Leiden.CETP mice. J Pineal Res. 2020;68:e12614.","journal-title":"J Pineal Res"},{"key":"723_CR21","doi-asserted-by":"publisher","first-page":"e12514","DOI":"10.1111\/jpi.12514","volume":"65","author":"A Galano","year":"2018","unstructured":"Galano A, Reiter RJ. Melatonin and its metabolites vs oxidative stress: From individual actions to collective protection. J Pineal Res. 2018;65:e12514.","journal-title":"J Pineal Res"},{"key":"723_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/jpi.12267","volume":"59","author":"LC Manchester","year":"2015","unstructured":"Manchester LC, Coto-Montes A, Boga JA, Andersen LP, Zhou Z, Galano A, Vriend J, Tan DX, Reiter RJ. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59:403\u201319.","journal-title":"J Pineal Res"},{"key":"723_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/jpi.12360","volume":"61","author":"RJ Reiter","year":"2016","unstructured":"Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61:253\u201378.","journal-title":"J Pineal Res"},{"key":"723_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00018-018-2963-0","volume":"76","author":"LG de Almeida Chuffa","year":"2019","unstructured":"de Almeida Chuffa LG, Seiva FRF, Cucielo MS, Silveira HS, Reiter RJ, Lupi LA. Mitochondrial functions and melatonin: a tour of the reproductive cancers. Cell Mol Life Sci. 2019;76:837\u201363.","journal-title":"Cell Mol Life Sci"},{"key":"723_CR25","doi-asserted-by":"publisher","first-page":"e12627","DOI":"10.1111\/jpi.12627","volume":"68","author":"YJ Niu","year":"2020","unstructured":"Niu YJ, Zhou W, Nie ZW, Shin KT, Cui XS. Melatonin enhances mitochondrial biogenesis and protects against rotenone-induced mitochondrial deficiency in early porcine embryos. J Pineal Res. 2020;68:e12627.","journal-title":"J Pineal Res"},{"key":"723_CR26","doi-asserted-by":"publisher","first-page":"e12642","DOI":"10.1111\/jpi.12642","volume":"68","author":"C Sun","year":"2020","unstructured":"Sun C, Lv T, Huang L, Liu X, Jin C, Lin X. Melatonin ameliorates aluminum toxicity through enhancing aluminum exclusion and reestablishing redox homeostasis in roots of wheat. J Pineal Res. 2020;68:e12642.","journal-title":"J Pineal Res"},{"key":"723_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/jpi.12026","volume":"54","author":"DX Tan","year":"2013","unstructured":"Tan DX, Manchester LC, Liu X, Rosales-Corral SA, Acuna-Castroviejo D, Reiter RJ. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin\u2019s primary function and evolution in eukaryotes. J Pineal Res. 2013;54:127\u201338.","journal-title":"J Pineal Res"},{"key":"723_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jpi.12137","volume":"56","author":"J Cipolla-Neto","year":"2014","unstructured":"Cipolla-Neto J, Amaral FG, Afeche SC, Tan DX, Reiter RJ. Melatonin, energy metabolism, and obesity: a review. J Pineal Res. 2014;56:371\u201381.","journal-title":"J Pineal Res"},{"key":"723_CR29","doi-asserted-by":"publisher","first-page":"e12613","DOI":"10.1111\/jpi.12613","volume":"68","author":"A Gonzalez-Candia","year":"2020","unstructured":"Gonzalez-Candia A, Candia AA, Figueroa EG, Feixes E, Gonzalez-Candia C, Aguilar SA, Ebensperger G, Reyes RV, Llanos AJ, Herrera EA. Melatonin long-lasting beneficial effects on pulmonary vascular reactivity and redox balance in chronic hypoxic ovine neonates. J Pineal Res. 2020;68:e12613.","journal-title":"J Pineal Res"},{"key":"723_CR30","doi-asserted-by":"publisher","first-page":"e12603","DOI":"10.1111\/jpi.12603","volume":"67","author":"J Leem","year":"2019","unstructured":"Leem J, Bai GY, Kim JS, Oh JS. Melatonin protects mouse oocytes from DNA damage by enhancing nonhomologous end-joining repair. J Pineal Res. 2019;67:e12603.","journal-title":"J Pineal Res"},{"key":"723_CR31","doi-asserted-by":"publisher","first-page":"e12587","DOI":"10.1111\/jpi.12587","volume":"67","author":"Z Ma","year":"2019","unstructured":"Ma Z, Liu D, Di S, Zhang Z, Li W, Zhang J, Xu L, Guo K, Zhu Y, Li X, et al. Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment. J Pineal Res. 2019;67:e12587.","journal-title":"J Pineal Res"},{"key":"723_CR32","doi-asserted-by":"publisher","first-page":"e12534","DOI":"10.1111\/jpi.12534","volume":"66","author":"JA Boga","year":"2019","unstructured":"Boga JA, Caballero B, Potes Y, Perez-Martinez Z, Reiter RJ, Vega-Naredo I, Coto-Montes A. Therapeutic potential of melatonin related to its role as an autophagy regulator: a review. J Pineal Res. 2019;66:e12534.","journal-title":"J Pineal Res"},{"key":"723_CR33","doi-asserted-by":"publisher","first-page":"e12516","DOI":"10.1111\/jpi.12516","volume":"65","author":"Y Qian","year":"2018","unstructured":"Qian Y, Han Q, Zhao X, Song J, Cheng Y, Fang Z, Ouyang Y, Yuan WE, Fan C. 3D melatonin nerve scaffold reduces oxidative stress and inflammation and increases autophagy in peripheral nerve regeneration. J Pineal Res. 2018;65:e12516.","journal-title":"J Pineal Res"},{"key":"723_CR34","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.7150\/thno.34327","volume":"9","author":"T Tian","year":"2019","unstructured":"Tian T, Li J, Li Y, Lu YX, Tang YL, Wang H, Zheng F, Shi D, Long Q, Chen M, et al. Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification. Theranostics. 2019;9:3768\u201379.","journal-title":"Theranostics"},{"key":"723_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/jpi.12285","volume":"60","author":"HQ Ju","year":"2016","unstructured":"Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, et al. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. J Pineal Res. 2016;60:27\u201338.","journal-title":"J Pineal Res"},{"key":"723_CR36","doi-asserted-by":"publisher","first-page":"e12394","DOI":"10.1111\/jpi.12370","volume":"62","author":"SC Su","year":"2017","unstructured":"Su SC, Hsieh MJ, Yang WE, Chung WH, Reiter RJ, Yang SF. Cancer metastasis: mechanisms of inhibition by melatonin. J Pineal Res. 2017;62:e12394.","journal-title":"J Pineal Res"},{"key":"723_CR37","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s13197-013-1221-6","volume":"51","author":"D Karunanithi","year":"2014","unstructured":"Karunanithi D, Radhakrishna A, Sivaraman KP, Biju VM. Quantitative determination of melatonin in milk by LC-MS\/MS. J Food Sci Technol. 2014;51:805\u201312.","journal-title":"J Food Sci Technol"},{"key":"723_CR38","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3109\/07420528.2015.1102149","volume":"32","author":"A Asher","year":"2015","unstructured":"Asher A, Shabtay A, Brosh A, Eitam H, Agmon R, Cohen-Zinder M, Zubidat AE, Haim A. \u201cChrono-functional milk\u201d: the difference between melatonin concentrations in night-milk versus day-milk under different night illumination conditions. Chronobiol Int. 2015;32:1409\u201316.","journal-title":"Chronobiol Int"},{"key":"723_CR39","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/jsfa.6480","volume":"94","author":"MP Milagres","year":"2014","unstructured":"Milagres MP, Minim VP, Minim LA, Simiqueli AA, Moraes LE, Martino HS. Night milking adds value to cow\u2019s milk. J Sci Food Agric. 2014;94:1688\u201392.","journal-title":"J Sci Food Agric"},{"key":"723_CR40","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/cells8070681","volume":"8","author":"B Salehi","year":"2019","unstructured":"Salehi B, Sharopov F, Fokou PVT, Kobylinska A, Jonge L, Tadio K, Sharifi-Rad J, Posmyk MM, Martorell M, Martins N, Iriti M. Melatonin in medicinal and food plants: occurrence, bioavailability, and health potential for humans. Cells. 2019;8:681.","journal-title":"Cells"},{"key":"723_CR41","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/jpi.12025","volume":"55","author":"M Sae-Teaw","year":"2013","unstructured":"Sae-Teaw M, Johns J, Johns NP, Subongkot S. Serum melatonin levels and antioxidant capacities after consumption of pineapple, orange, or banana by healthy male volunteers. J Pineal Res. 2013;55:58\u201364.","journal-title":"J Pineal Res"},{"key":"723_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0024-3205(03)00252-2","volume":"73","author":"G Chen","year":"2003","unstructured":"Chen G, Huo Y, Tan DX, Liang Z, Zhang W, Zhang Y. Melatonin in Chinese medicinal herbs. Life Sci. 2003;73:19\u201326.","journal-title":"Life Sci"},{"key":"723_CR43","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2174\/1874609811205030002","volume":"5","author":"VN Anisimov","year":"2012","unstructured":"Anisimov VN, Vinogradova IA, Panchenko AV, Popovich IG, Zabezhinski MA. Light-at-night-induced circadian disruption, cancer and aging. Curr Aging Sci. 2012;5:170\u20137.","journal-title":"Curr Aging Sci"},{"key":"723_CR44","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/aje\/kwj232","volume":"164","author":"T Kubo","year":"2006","unstructured":"Kubo T, Ozasa K, Mikami K, Wakai K, Fujino Y, Watanabe Y, Miki T, Nakao M, Hayashi K, Suzuki K, et al. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am J Epidemiol. 2006;164:549\u201355.","journal-title":"Am J Epidemiol"},{"key":"723_CR45","doi-asserted-by":"publisher","first-page":"250","DOI":"10.5271\/sjweh.3626","volume":"43","author":"K Papantoniou","year":"2017","unstructured":"Papantoniou K, Castano-Vinyals G, Espinosa A, Turner MC, Alonso-Aguado MH, Martin V, Aragones N, Perez-Gomez B, Pozo BM, Gomez-Acebo I, et al. Shift work and colorectal cancer risk in the MCC-Spain case-control study. Scand J Work Environ Health. 2017;43:250\u20139.","journal-title":"Scand J Work Environ Health"},{"key":"723_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2014.07.008","volume":"67","author":"LG Sigurdardottir","year":"2015","unstructured":"Sigurdardottir LG, Markt SC, Rider JR, Haneuse S, Fall K, Schernhammer ES, Tamimi RM, Flynn-Evans E, Batista JL, Launer L, et al. Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men. Eur Urol. 2015;67:191\u20134.","journal-title":"Eur Urol"},{"key":"723_CR47","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/jpi.12227","volume":"58","author":"Z Xin","year":"2015","unstructured":"Xin Z, Jiang S, Jiang P, Yan X, Fan C, Di S, Wu G, Yang Y, Reiter RJ, Ji G. Melatonin as a treatment for gastrointestinal cancer: a review. J Pineal Res. 2015;58:375\u201387.","journal-title":"J Pineal Res"},{"key":"723_CR48","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/00001648-199809000-00004","volume":"9","author":"M Feychting","year":"1998","unstructured":"Feychting M, Osterlund B, Ahlbom A. Reduced cancer incidence among the blind. Epidemiology. 1998;9:490\u20134.","journal-title":"Epidemiology"},{"key":"723_CR49","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s10552-009-9405-0","volume":"20","author":"EE Flynn-Evans","year":"2009","unstructured":"Flynn-Evans EE, Stevens RG, Tabandeh H, Schernhammer ES, Lockley SW. Total visual blindness is protective against breast cancer. Cancer Causes Control. 2009;20:1753\u20136.","journal-title":"Cancer Causes Control"},{"key":"723_CR50","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/00001648-199809000-00002","volume":"9","author":"RA Hahn","year":"1998","unstructured":"Hahn RA. Does blindness protect against cancers? Epidemiology. 1998;9:481\u20133.","journal-title":"Epidemiology"},{"key":"723_CR51","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1054\/bjoc.2000.1617","volume":"84","author":"J Kliukiene","year":"2001","unstructured":"Kliukiene J, Tynes T, Andersen A. Risk of breast cancer among Norwegian women with visual impairment. Br J Cancer. 2001;84:397\u20139.","journal-title":"Br J Cancer"},{"key":"723_CR52","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(07)70373-X","volume":"8","author":"K Straif","year":"2007","unstructured":"Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Benbrahim-Tallaa L, Cogliano V, WHOIAFRoCMW Group. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007;8:1065\u20136.","journal-title":"Lancet Oncol"},{"key":"723_CR53","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1600-079X.1985.tb00633.x","volume":"2","author":"C Bartsch","year":"1985","unstructured":"Bartsch C, Bartsch H, Fluchter SH, Attanasio A, Gupta D. Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the prostate: relationship with the pituitary hormones. J Pineal Res. 1985;2:121\u201332.","journal-title":"J Pineal Res"},{"key":"723_CR54","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/ijc.29400","volume":"137","author":"K Papantoniou","year":"2015","unstructured":"Papantoniou K, Castano-Vinyals G, Espinosa A, Aragones N, Perez-Gomez B, Burgos J, Gomez-Acebo I, Llorca J, Peiro R, Jimenez-Moleon JJ, et al. Night shift work, chronotype and prostate cancer risk in the MCC-Spain case-control study. Int J Cancer. 2015;137:1147\u201357.","journal-title":"Int J Cancer"},{"key":"723_CR55","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/oemed-2018-105009","volume":"75","author":"MG Wendeu-Foyet","year":"2018","unstructured":"Wendeu-Foyet MG, Bayon V, Cenee S, Tretarre B, Rebillard X, Cancel-Tassin G, Cussenot O, Lamy PJ, Faraut B, Ben Khedher S, et al. Night work and prostate cancer risk: results from the EPICAP study. Occup Environ Med. 2018;75:573\u201381.","journal-title":"Occup Environ Med"},{"key":"723_CR56","doi-asserted-by":"publisher","first-page":"29606","DOI":"10.1038\/srep29606","volume":"6","author":"SY Tai","year":"2016","unstructured":"Tai SY, Huang SP, Bao BY, Wu MT. Urinary melatonin-sulfate\/cortisol ratio and the presence of prostate cancer: a case-control study. Sci Rep. 2016;6:29606.","journal-title":"Sci Rep"},{"key":"723_CR57","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/07420528.2016.1259241","volume":"34","author":"KY Kim","year":"2017","unstructured":"Kim KY, Lee E, Kim YJ, Kim J. The association between artificial light at night and prostate cancer in Gwangju City and South Jeolla Province of South Korea. Chronobiol Int. 2017;34:203\u201311.","journal-title":"Chronobiol Int"},{"key":"723_CR58","doi-asserted-by":"publisher","first-page":"e102776","DOI":"10.1371\/journal.pone.0102776","volume":"9","author":"DE Blask","year":"2014","unstructured":"Blask DE, Dauchy RT, Dauchy EM, Mao L, Hill SM, Greene MW, Belancio VP, Sauer LA, Davidson L. Light exposure at night disrupts host\/cancer circadian regulatory dynamics: impact on the Warburg effect, lipid signaling and tumor growth prevention. PLoS ONE. 2014;9:e102776.","journal-title":"PLoS ONE"},{"key":"723_CR59","first-page":"473","volume":"65","author":"RT Dauchy","year":"2015","unstructured":"Dauchy RT, Hoffman AE, Wren-Dail MA, Hanifin JP, Warfield B, Brainard GC, Xiang S, Yuan L, Hill SM, Belancio VP, et al. Daytime blue light enhances the nighttime circadian melatonin inhibition of human prostate cancer growth. Comp Med. 2015;65:473\u201385.","journal-title":"Comp Med"},{"key":"723_CR60","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.eururo.2018.09.019","volume":"75","author":"RE Graff","year":"2019","unstructured":"Graff RE, Kachuri L, Witte JS. Personalized prostate cancer screening based on a single midlife prostate-specific antigen measurement. Eur Urol. 2019;75:408\u20139.","journal-title":"Eur Urol"},{"key":"723_CR61","doi-asserted-by":"publisher","first-page":"576","DOI":"10.7150\/ijbs.8479","volume":"10","author":"HV Heemers","year":"2014","unstructured":"Heemers HV. Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities? Int J Biol Sci. 2014;10:576\u201387.","journal-title":"Int J Biol Sci"},{"key":"723_CR62","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/andr.12186","volume":"4","author":"S La Vignera","year":"2016","unstructured":"La Vignera S, Condorelli RA, Russo GI, Morgia G, Calogero AE. Endocrine control of benign prostatic hyperplasia. Andrology. 2016;4:404\u201311.","journal-title":"Andrology"},{"key":"723_CR63","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nrurol.2014.107","volume":"11","author":"R Phillips","year":"2014","unstructured":"Phillips R. Prostate cancer: novel targeting of androgen signalling in CRPC. Nat Rev Urol. 2014;11:303.","journal-title":"Nat Rev Urol"},{"key":"723_CR64","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1210\/er.2004-0017","volume":"26","author":"F Labrie","year":"2005","unstructured":"Labrie F, Belanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J, Candas B. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev. 2005;26:361\u201379.","journal-title":"Endocr Rev"},{"key":"723_CR65","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jsbmb.2008.11.004","volume":"113","author":"F Labrie","year":"2009","unstructured":"Labrie F, Cusan L, Gomez JL, Martel C, Berube R, Belanger P, Belanger A, Vandenput L, Mellstrom D, Ohlsson C. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol. 2009;113:52\u20136.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"723_CR66","first-page":"193","volume":"55","author":"F Labrie","year":"1985","unstructured":"Labrie F, Dupont A, Belanger A. Complete androgen blockade for the treatment of prostate cancer. Important Adv Oncol. 1985;55:193\u2013217.","journal-title":"Important Adv Oncol"},{"key":"723_CR67","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1210\/endo-126-5-2359","volume":"126","author":"DA Husmann","year":"1990","unstructured":"Husmann DA, Wilson CM, McPhaul MJ, Tilley WD, Wilson JD. Antipeptide antibodies to two distinct regions of the androgen receptor localize the receptor protein to the nuclei of target cells in the rat and human prostate. Endocrinology. 1990;126:2359\u201368.","journal-title":"Endocrinology"},{"key":"723_CR68","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1210\/endo-127-6-3180","volume":"127","author":"M Sar","year":"1990","unstructured":"Sar M, Lubahn DB, French FS, Wilson EM. Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology. 1990;127:3180\u20136.","journal-title":"Endocrinology"},{"key":"723_CR69","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/42750","volume":"387","author":"DM Heery","year":"1997","unstructured":"Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997;387:733\u20136.","journal-title":"Nature"},{"key":"723_CR70","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/0960-0760(93)90316-O","volume":"46","author":"H Suzuki","year":"1993","unstructured":"Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol. 1993;46:759\u201365.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"723_CR71","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ijc.10495","volume":"100","author":"K Steketee","year":"2002","unstructured":"Steketee K, Timmerman L, Ziel-van der Made AC, Doesburg P, Brinkmann AO, Trapman J. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer. 2002;100:309\u201317.","journal-title":"Int J Cancer"},{"key":"723_CR72","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1074\/jbc.M109.039958","volume":"285","author":"DJ van de Wijngaart","year":"2010","unstructured":"van de Wijngaart DJ, Molier M, Lusher SJ, Hersmus R, Jenster G, Trapman J, Dubbink HJ. Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H. J Biol Chem. 2010;285:5097\u2013105.","journal-title":"J Biol Chem"},{"key":"723_CR73","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13059-015-0864-1","volume":"17","author":"N Lallous","year":"2016","unstructured":"Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW, LeBihan S, et al. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol. 2016;17:10.","journal-title":"Genome Biol"},{"key":"723_CR74","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"723_CR75","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jsbmb.2006.02.004","volume":"99","author":"F Labrie","year":"2006","unstructured":"Labrie F, Belanger A, Belanger P, Berube R, Martel C, Cusan L, Gomez J, Candas B, Castiel I, Chaussade V, et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol. 2006;99:182\u20138.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"723_CR76","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/pros.21107","volume":"70","author":"H Kawata","year":"2010","unstructured":"Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate. 2010;70:745\u201354.","journal-title":"Prostate"},{"key":"723_CR77","doi-asserted-by":"publisher","first-page":"254ra125","DOI":"10.1126\/scitranslmed.3009448","volume":"6","author":"S Carreira","year":"2014","unstructured":"Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel JS, Pezaro C, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014;6:254ra125.","journal-title":"Sci Transl Med"},{"key":"723_CR78","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/pcan.2016.17","volume":"19","author":"ES Antonarakis","year":"2016","unstructured":"Antonarakis ES, Armstrong AJ, Dehm SM, Luo J. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis. 2016;19:231\u201341.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"723_CR79","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4103\/1008-682X.178490","volume":"18","author":"J Luo","year":"2016","unstructured":"Luo J. Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. Asian J Androl. 2016;18:580\u20135.","journal-title":"Asian J Androl"},{"key":"723_CR80","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.eururo.2017.11.038","volume":"73","author":"J Luo","year":"2018","unstructured":"Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, et al. Role of androgen receptor variants in prostate cancer: report from the 2017 mission androgen receptor variants meeting. Eur Urol. 2018;73:715\u201323.","journal-title":"Eur Urol"},{"key":"723_CR81","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1600-079X.1995.tb00146.x","volume":"18","author":"TM Molis","year":"1995","unstructured":"Molis TM, Spriggs LL, Jupiter Y, Hill SM. Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer. J Pineal Res. 1995;18:93\u2013103.","journal-title":"J Pineal Res"},{"key":"723_CR82","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1096\/fasebj.13.8.857","volume":"13","author":"AG Rato","year":"1999","unstructured":"Rato AG, Pedrero JG, Martinez MA, del Rio B, Lazo PS, Ramos S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J. 1999;13:857\u201368.","journal-title":"FASEB J"},{"key":"723_CR83","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1210\/mend.13.12.0382","volume":"13","author":"LV Nazareth","year":"1999","unstructured":"Nazareth LV, Stenoien DL, Bingman WE 3rd, James AJ, Wu C, Zhang Y, Edwards DP, Mancini M, Marcelli M, Lamb DJ, Weigel NL. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1). Mol Endocrinol. 1999;13:2065\u201375.","journal-title":"Mol Endocrinol"},{"key":"723_CR84","doi-asserted-by":"publisher","first-page":"8772","DOI":"10.1074\/jbc.275.12.8772","volume":"275","author":"Y Kobayashi","year":"2000","unstructured":"Kobayashi Y, Kume A, Li M, Doyu M, Hata M, Ohtsuka K, Sobue G. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J Biol Chem. 2000;275:8772\u20138.","journal-title":"J Biol Chem"},{"key":"723_CR85","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0896-6273(00)80405-5","volume":"19","author":"CA Ross","year":"1997","unstructured":"Ross CA. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron. 1997;19:1147\u201350.","journal-title":"Neuron"},{"key":"723_CR86","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/pros.1129","volume":"49","author":"A Rimler","year":"2001","unstructured":"Rimler A, Culig Z, Levy-Rimler G, Lupowitz Z, Klocker H, Matzkin H, Bartsch G, Zisapel N. Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. Prostate. 2001;49:145\u201354.","journal-title":"Prostate"},{"key":"723_CR87","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0960-0760(02)00050-X","volume":"81","author":"A Rimler","year":"2002","unstructured":"Rimler A, Culig Z, Lupowitz Z, Zisapel N. Nuclear exclusion of the androgen receptor by melatonin. J Steroid Biochem Mol Biol. 2002;81:77\u201384.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"Suppl 1","key":"723_CR88","first-page":"45","volume":"23","author":"A Rimler","year":"2002","unstructured":"Rimler A, Lupowitz Z, Zisapel N. Differential regulation by melatonin of cell growth and androgen receptor binding to the androgen response element in prostate cancer cells. Neuro Endocrinol Lett. 2002;23(Suppl 1):45\u20139.","journal-title":"Neuro Endocrinol Lett"},{"key":"723_CR89","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/PL00000842","volume":"58","author":"Z Lupowitz","year":"2001","unstructured":"Lupowitz Z, Rimler A, Zisapel N. Evaluation of signal transduction pathways mediating the nuclear exclusion of the androgen receptor by melatonin. Cell Mol Life Sci. 2001;58:2129\u201335.","journal-title":"Cell Mol Life Sci"},{"key":"723_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02686113","volume":"31","author":"A Rimler","year":"2007","unstructured":"Rimler A, Jockers R, Lupowitz Z, Zisapel N. Gi and RGS proteins provide biochemical control of androgen receptor nuclear exclusion. J Mol Neurosci. 2007;31:1\u201312.","journal-title":"J Mol Neurosci"},{"key":"723_CR91","first-page":"52","volume":"11","author":"LG Gomella","year":"2009","unstructured":"Gomella LG. Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev Urol. 2009;11:52\u201360.","journal-title":"Rev Urol"},{"key":"723_CR92","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3322\/canjclin.52.3.154","volume":"52","author":"BA Hellerstedt","year":"2002","unstructured":"Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002;52:154\u201379.","journal-title":"CA Cancer J Clin"},{"key":"723_CR93","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/cncr.28485","volume":"120","author":"JN Wu","year":"2014","unstructured":"Wu JN, Fish KM, Evans CP, Devere White RW, Dall\u2019Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014;120:818\u201323.","journal-title":"Cancer"},{"key":"723_CR94","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0002-9440(10)63112-4","volume":"164","author":"J Holzbeierlein","year":"2004","unstructured":"Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217\u201327.","journal-title":"Am J Pathol"},{"key":"723_CR95","doi-asserted-by":"publisher","first-page":"6718","DOI":"10.1038\/sj.onc.1204889","volume":"20","author":"S Mousses","year":"2001","unstructured":"Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, Pretlow T, Elkahloun AG, Trepel JB, Kallioniemi OP. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene. 2001;20:6718\u201323.","journal-title":"Oncogene"},{"key":"723_CR96","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33\u20139.","journal-title":"Nat Med"},{"key":"723_CR97","doi-asserted-by":"publisher","first-page":"10613","DOI":"10.1158\/0008-5472.CAN-06-0028","volume":"66","author":"H Cheng","year":"2006","unstructured":"Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res. 2006;66:10613\u201320.","journal-title":"Cancer Res"},{"key":"723_CR98","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.CCR-08-1726","volume":"15","author":"R Snoek","year":"2009","unstructured":"Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res. 2009;15:39\u201347.","journal-title":"Clin Cancer Res"},{"key":"723_CR99","first-page":"1008","volume":"62","author":"OL Zegarra-Moro","year":"2002","unstructured":"Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 2002;62:1008\u201313.","journal-title":"Cancer Res"},{"key":"723_CR100","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrurol.2012.237","volume":"10","author":"Y Zong","year":"2013","unstructured":"Zong Y, Goldstein AS. Adaptation or selection\u2014mechanisms of castration-resistant prostate cancer. Nat Rev Urol. 2013;10:90\u20138.","journal-title":"Nat Rev Urol"},{"key":"723_CR101","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pros.10098","volume":"52","author":"SW Siu","year":"2002","unstructured":"Siu SW, Lau KW, Tam PC, Shiu SY. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate. 2002;52:106\u201322.","journal-title":"Prostate"},{"key":"723_CR102","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1034\/j.1600-079X.2000.d01-64.x","volume":"29","author":"SC Xi","year":"2000","unstructured":"Xi SC, Tam PC, Brown GM, Pang SF, Shiu SY. Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells. J Pineal Res. 2000;29:172\u201383.","journal-title":"J Pineal Res"},{"key":"723_CR103","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/1097-0045(200101)46:1<52::AID-PROS1008>3.0.CO;2-Z","volume":"46","author":"SC Xi","year":"2001","unstructured":"Xi SC, Siu SW, Fong SW, Shiu SY. Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate. 2001;46:52\u201361.","journal-title":"Prostate"},{"key":"723_CR104","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/ijms18061130","volume":"18","author":"VWS Liu","year":"2017","unstructured":"Liu VWS, Yau WL, Tam CW, Yao KM, Shiu SYW. Melatonin inhibits androgen receptor splice variant-7 (AR-V7)-induced nuclear factor-kappa B (NF-kappaB) activation and NF-kappaB activator-induced AR-V7 expression in prostate cancer cells: potential implications for the use of melatonin in castration-resistant prostate cancer (CRPC) therapy. Int J Mol Sci. 2017;18:1130.","journal-title":"Int J Mol Sci"},{"key":"723_CR105","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000474446","volume":"31","author":"P Lissoni","year":"1997","unstructured":"Lissoni P, Cazzaniga M, Tancini G, Scardino E, Musci R, Barni S, Maffezzini M, Meroni T, Rocco F, Conti A, Maestroni G. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. Eur Urol. 1997;31:178\u201381.","journal-title":"Eur Urol"},{"key":"723_CR106","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.18632\/oncotarget.27757","volume":"11","author":"GM Zharinov","year":"2020","unstructured":"Zharinov GM, Bogomolov OA, Chepurnaya IV, Neklasova NY, Anisimov VN. Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment. Oncotarget. 2020;11:3723\u20139.","journal-title":"Oncotarget"},{"key":"723_CR107","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21141","volume":"62","author":"MD Galsky","year":"2012","unstructured":"Galsky MD, Small AC, Tsao CK, Oh WK. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes. CA Cancer J Clin. 2012;62:299\u2013308.","journal-title":"CA Cancer J Clin"},{"key":"723_CR108","doi-asserted-by":"publisher","first-page":"36674","DOI":"10.18632\/oncotarget.16230","volume":"8","author":"K Cui","year":"2017","unstructured":"Cui K, Li X, Du Y, Tang X, Arai S, Geng Y, Xi Y, Xu H, Zhou Y, Ma W, Zhang T. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison. Oncotarget. 2017;8:36674\u201384.","journal-title":"Oncotarget"},{"key":"723_CR109","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180\u201392.","journal-title":"Int J Clin Pract"},{"key":"723_CR110","doi-asserted-by":"publisher","first-page":"8734","DOI":"10.1073\/pnas.92.19.8734","volume":"92","author":"SM Reppert","year":"1995","unstructured":"Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA. 1995;92:8734\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"723_CR111","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/0896-6273(94)90054-X","volume":"13","author":"SM Reppert","year":"1994","unstructured":"Reppert SM, Tsai T, Roca AL, Sauman I. Cloning of a structural and functional homolog of the circadian clock gene period from the giant silkmoth Antheraea pernyi. Neuron. 1994;13:1167\u201376.","journal-title":"Neuron"},{"key":"723_CR112","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/0896-6273(94)90055-8","volume":"13","author":"SM Reppert","year":"1994","unstructured":"Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron. 1994;13:1177\u201385.","journal-title":"Neuron"},{"key":"723_CR113","doi-asserted-by":"publisher","first-page":"e12606","DOI":"10.1111\/jpi.12606","volume":"67","author":"E Cecon","year":"2019","unstructured":"Cecon E, Liu L, Jockers R. Melatonin receptor structures shed new light on melatonin research. J Pineal Res. 2019;67:e12606.","journal-title":"J Pineal Res"},{"key":"723_CR114","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1111\/bph.13950","volume":"175","author":"E Cecon","year":"2018","unstructured":"Cecon E, Oishi A, Jockers R. Melatonin receptors: molecular pharmacology and signalling in the context of system bias. Br J Pharmacol. 2018;175:3263\u201380.","journal-title":"Br J Pharmacol"},{"key":"723_CR115","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1034\/j.1600-079x.2001.310213.x","volume":"31","author":"K Winczyk","year":"2001","unstructured":"Winczyk K, Pawlikowski M, Karasek M. Melatonin and RZR\/ROR receptor ligand CGP 52608 induce apoptosis in the murine colonic cancer. J Pineal Res. 2001;31:179\u201382.","journal-title":"J Pineal Res"},{"issue":"Suppl 1","key":"723_CR116","first-page":"50","volume":"23","author":"K Winczyk","year":"2002","unstructured":"Winczyk K, Pawlikowski M, Lawnicka H, Kunert-Radek J, Spadoni G, Tarzia G, Karasek M. Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo. Neuro Endocrinol Lett. 2002;23(Suppl 1):50\u20134.","journal-title":"Neuro Endocrinol Lett"},{"key":"723_CR117","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s12029-013-9552-0","volume":"45","author":"NN Nasrabadi","year":"2014","unstructured":"Nasrabadi NN, Ataee R, Abediankenari S, Shokrzadeh M, Najafi M, Hoseini SV, Jan HH. Expression of MT2 receptor in patients with gastric adenocarcinoma and its relationship with clinicopathological features. J Gastrointest Cancer. 2014;45:54\u201360.","journal-title":"J Gastrointest Cancer"},{"key":"723_CR118","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1309\/1T4V-CT1G-UBJP-3EHP","volume":"118","author":"DC Dillon","year":"2002","unstructured":"Dillon DC, Easley SE, Asch BB, Cheney RT, Brydon L, Jockers R, Winston JS, Brooks JS, Hurd T, Asch HL. Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol. 2002;118:451\u20138.","journal-title":"Am J Clin Pathol"},{"key":"723_CR119","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0304-3835(01)00873-4","volume":"179","author":"PT Ram","year":"2002","unstructured":"Ram PT, Dai J, Yuan L, Dong C, Kiefer TL, Lai L, Hill SM. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett. 2002;179:141\u201350.","journal-title":"Cancer Lett"},{"key":"723_CR120","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1034\/j.1600-079X.2003.00074.x","volume":"35","author":"SY Shiu","year":"2003","unstructured":"Shiu SY, Law IC, Lau KW, Tam PC, Yip AW, Ng WT. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res. 2003;35:177\u201382.","journal-title":"J Pineal Res"},{"key":"723_CR121","doi-asserted-by":"publisher","first-page":"13719","DOI":"10.1038\/ncomms13719","volume":"7","author":"A Revandkar","year":"2016","unstructured":"Revandkar A, Perciato ML, Toso A, Alajati A, Chen J, Gerber H, Dimitrov M, Rinaldi A, Delaleu N, Pasquini E, et al. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence. Nat Commun. 2016;7:13719.","journal-title":"Nat Commun"},{"key":"723_CR122","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1158\/0008-5472.CAN-08-3115","volume":"69","author":"S Roy","year":"2009","unstructured":"Roy S, Gu M, Ramasamy K, Singh RP, Agarwal C, Siriwardana S, Sclafani RA, Agarwal R. p21\/Cip1 and p27\/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer. Cancer Res. 2009;69:1166\u201373.","journal-title":"Cancer Res"},{"key":"723_CR123","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/S0002-9440(10)65517-4","volume":"155","author":"AM De Marzo","year":"1999","unstructured":"De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155:1985\u201392.","journal-title":"Am J Pathol"},{"key":"723_CR124","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0002-9440(10)65277-7","volume":"154","author":"RV Lloyd","year":"1999","unstructured":"Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 1999;154:313\u201323.","journal-title":"Am J Pathol"},{"key":"723_CR125","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1600-079X.2012.01026.x","volume":"54","author":"SY Shiu","year":"2013","unstructured":"Shiu SY, Leung WY, Tam CW, Liu VW, Yao KM. Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-kappaB): potential implications on prostate cancer chemoprevention and therapy. J Pineal Res. 2013;54:69\u201379.","journal-title":"J Pineal Res"},{"key":"723_CR126","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1600-079X.2010.00795.x","volume":"49","author":"SY Shiu","year":"2010","unstructured":"Shiu SY, Pang B, Tam CW, Yao KM. Signal transduction of receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells involves dual activation of Galpha(s) and Galpha(q) proteins. J Pineal Res. 2010;49:301\u201311.","journal-title":"J Pineal Res"},{"key":"723_CR127","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1600-079X.2006.00406.x","volume":"42","author":"CW Tam","year":"2007","unstructured":"Tam CW, Mo CW, Yao KM, Shiu SY. Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention. J Pineal Res. 2007;42:191\u2013202.","journal-title":"J Pineal Res"},{"key":"723_CR128","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27\u201347.","journal-title":"Cell Metab"},{"key":"723_CR129","first-page":"670","volume":"21","author":"P Som","year":"1980","unstructured":"Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, Oster ZH, Sacker DF, Shiue CY, Turner H, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670\u20135.","journal-title":"J Nucl Med"},{"key":"723_CR130","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1085\/jgp.8.6.519","volume":"8","author":"O Warburg","year":"1927","unstructured":"Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519\u201330.","journal-title":"J Gen Physiol"},{"key":"723_CR131","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/jcp.2005.027664","volume":"59","author":"GD Dakubo","year":"2006","unstructured":"Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol. 2006;59:10\u20136.","journal-title":"J Clin Pathol"},{"key":"723_CR132","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/sj.pcan.4500712","volume":"7","author":"LC Costello","year":"2004","unstructured":"Costello LC, Feng P, Milon B, Tan M, Franklin RB. Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis. 2004;7:111\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"723_CR133","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1476-4598-5-17","volume":"5","author":"LC Costello","year":"2006","unstructured":"Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer. 2006;5:17.","journal-title":"Mol Cancer"},{"key":"723_CR134","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.bbalip.2013.03.010","volume":"1831","author":"G Zadra","year":"2013","unstructured":"Zadra G, Photopoulos C, Loda M. The fat side of prostate cancer. Biochim Biophys Acta. 2013;1831:1518\u201332.","journal-title":"Biochim Biophys Acta"},{"key":"723_CR135","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0022-5347(17)64003-5","volume":"92","author":"JF Cooper","year":"1964","unstructured":"Cooper JF, Farid I. The role of citric acid in the physiology of the prostate. 3. Lactate\/citrate ratios in benign and malignant prostatic homogenates as an index of prostatic malignancy. J Urol. 1964;92:533\u20136.","journal-title":"J Urol"},{"key":"723_CR136","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000012183","volume":"59","author":"LC Costello","year":"2000","unstructured":"Costello LC, Franklin RB. The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology. 2000;59:269\u201382.","journal-title":"Oncology"},{"key":"723_CR137","doi-asserted-by":"publisher","first-page":"28875","DOI":"10.1074\/jbc.272.46.28875","volume":"272","author":"LC Costello","year":"1997","unstructured":"Costello LC, Liu Y, Franklin RB, Kennedy MC. Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. J Biol Chem. 1997;272:28875\u201381.","journal-title":"J Biol Chem"},{"key":"723_CR138","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1002\/ijc.29576","volume":"137","author":"AM Mondul","year":"2015","unstructured":"Mondul AM, Moore SC, Weinstein SJ, Karoly ED, Sampson JN, Albanes D. Metabolomic analysis of prostate cancer risk in a prospective cohort: the alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study. Int J Cancer. 2015;137:2124\u201332.","journal-title":"Int J Cancer"},{"key":"723_CR139","doi-asserted-by":"publisher","first-page":"e0135704","DOI":"10.1371\/journal.pone.0135704","volume":"10","author":"A Dueregger","year":"2015","unstructured":"Dueregger A, Schopf B, Eder T, Hofer J, Gnaiger E, Aufinger A, Kenner L, Perktold B, Ramoner R, Klocker H, Eder IE. Differential utilization of dietary fatty acids in benign and malignant cells of the prostate. PLoS ONE. 2015;10:e0135704.","journal-title":"PLoS ONE"},{"key":"723_CR140","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3389\/fonc.2016.00225","volume":"6","author":"C Testa","year":"2016","unstructured":"Testa C, Pultrone C, Manners DN, Schiavina R, Lodi R. Metabolic imaging in prostate cancer: where we are. Front Oncol. 2016;6:225.","journal-title":"Front Oncol"},{"key":"723_CR141","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1053\/j.semnuclmed.2004.06.004","volume":"34","author":"H Schoder","year":"2004","unstructured":"Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274\u201392.","journal-title":"Semin Nucl Med"},{"key":"723_CR142","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0014-5793(97)01178-2","volume":"416","author":"EJ Costa","year":"1997","unstructured":"Costa EJ, Shida CS, Biaggi MH, Ito AS, Lamy-Freund MT. How melatonin interacts with lipid bilayers: a study by fluorescence and ESR spectroscopies. FEBS Lett. 1997;416:103\u20136.","journal-title":"FEBS Lett"},{"key":"723_CR143","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/0883-2897(91)90132-5","volume":"18","author":"D Le Bars","year":"1991","unstructured":"Le Bars D, Thivolle P, Vitte PA, Bojkowski C, Chazot G, Arendt J, Frackowiak RS, Claustrat B. PET and plasma pharmacokinetic studies after bolus intravenous administration of [11C]melatonin in humans. Int J Rad Appl Instrum B. 1991;18:357\u201362.","journal-title":"Int J Rad Appl Instrum B"},{"key":"723_CR144","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1600-079X.2008.00581.x","volume":"45","author":"D Hevia","year":"2008","unstructured":"Hevia D, Sainz RM, Blanco D, Quiros I, Tan DX, Rodriguez C, Mayo JC. Melatonin uptake in prostate cancer cells: intracellular transport versus simple passive diffusion. J Pineal Res. 2008;45:247\u201357.","journal-title":"J Pineal Res"},{"key":"723_CR145","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/jpi.12210","volume":"58","author":"D Hevia","year":"2015","unstructured":"Hevia D, Gonzalez-Menendez P, Quiros-Gonzalez I, Miar A, Rodriguez-Garcia A, Tan DX, Reiter RJ, Mayo JC, Sainz RM. Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer. J Pineal Res. 2015;58:234\u201350.","journal-title":"J Pineal Res"},{"key":"723_CR146","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/cncr.11293","volume":"97","author":"JD Chandler","year":"2003","unstructured":"Chandler JD, Williams ED, Slavin JL, Best JD, Rogers S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer. 2003;97:2035\u201342.","journal-title":"Cancer"},{"key":"723_CR147","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40170-016-0149-5","volume":"4","author":"I Georgescu","year":"2016","unstructured":"Georgescu I, Gooding RJ, Doiron RC, Day A, Selvarajah S, Davidson C, Berman DM, Park PC. Molecular characterization of Gleason patterns 3 and 4 prostate cancer using reverse Warburg effect-associated genes. Cancer Metab. 2016;4:8.","journal-title":"Cancer Metab"},{"key":"723_CR148","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/jcb.23379","volume":"113","author":"K Reinicke","year":"2012","unstructured":"Reinicke K, Sotomayor P, Cisterna P, Delgado C, Nualart F, Godoy A. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Cell Biochem. 2012;113:553\u201362.","journal-title":"J Cell Biochem"},{"key":"723_CR149","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/pros.23448","volume":"78","author":"H Xiao","year":"2018","unstructured":"Xiao H, Wang J, Yan W, Cui Y, Chen Z, Gao X, Wen X, Chen J. GLUT1 regulates cell glycolysis and proliferation in prostate cancer. Prostate. 2018;78:86\u201394.","journal-title":"Prostate"},{"key":"723_CR150","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1007\/s00018-017-2616-8","volume":"74","author":"JC Mayo","year":"2017","unstructured":"Mayo JC, Sainz RM, Gonzalez-Menendez P, Hevia D, Cernuda-Cernuda R. Melatonin transport into mitochondria. Cell Mol Life Sci. 2017;74:3927\u201340.","journal-title":"Cell Mol Life Sci"},{"key":"723_CR151","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jpi.12390","volume":"62","author":"X Huo","year":"2017","unstructured":"Huo X, Wang C, Yu Z, Peng Y, Wang S, Feng S, Zhang S, Tian X, Sun C, Liu K, et al. Human transporters, PEPT1\/2, facilitate melatonin transportation into mitochondria of cancer cells: an implication of the therapeutic potential. J Pineal Res. 2017;62:536.","journal-title":"J Pineal Res"},{"key":"723_CR152","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.3390\/ijms18081620","volume":"18","author":"D Hevia","year":"2017","unstructured":"Hevia D, Gonzalez-Menendez P, Fernandez-Fernandez M, Cueto S, Rodriguez-Gonzalez P, Garcia-Alonso JI, Mayo JC, Sainz RM. Melatonin decreases glucose metabolism in prostate cancer cells: a (13)C stable isotope-resolved metabolomic study. Int J Mol Sci. 2017;18:1620.","journal-title":"Int J Mol Sci"},{"key":"723_CR153","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrc905","volume":"2","author":"R Kerbel","year":"2002","unstructured":"Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727\u201339.","journal-title":"Nat Rev Cancer"},{"key":"723_CR154","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249\u201357.","journal-title":"Nature"},{"key":"723_CR155","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"723_CR156","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.crad.2011.02.013","volume":"66","author":"J Jiang","year":"2011","unstructured":"Jiang J, Chen Y, Zhu Y, Yao X, Qi J. Contrast-enhanced ultrasonography for the detection and characterization of prostate cancer: correlation with microvessel density and Gleason score. Clin Radiol. 2011;66:732\u20137.","journal-title":"Clin Radiol"},{"key":"723_CR157","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.critrevonc.2013.01.002","volume":"87","author":"D Mukherji","year":"2013","unstructured":"Mukherji D, Temraz S, Wehbe D, Shamseddine A. Angiogenesis and anti-angiogenic therapy in prostate cancer. Crit Rev Oncol Hematol. 2013;87:122\u201331.","journal-title":"Crit Rev Oncol Hematol"},{"key":"723_CR158","first-page":"401","volume":"143","author":"N Weidner","year":"1993","unstructured":"Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401\u20139.","journal-title":"Am J Pathol"},{"key":"723_CR159","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0090-4295(99)00167-3","volume":"54","author":"JL Duque","year":"1999","unstructured":"Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 1999;54:523\u20137.","journal-title":"Urology"},{"key":"723_CR160","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijrobp.2006.08.077","volume":"67","author":"MM Green","year":"2007","unstructured":"Green MM, Hiley CT, Shanks JH, Bottomley IC, West CM, Cowan RA, Stratford IJ. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys. 2007;67:84\u201390.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"723_CR161","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1006\/bbrc.1998.9328","volume":"251","author":"S Sordello","year":"1998","unstructured":"Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun. 1998;251:287\u201390.","journal-title":"Biochem Biophys Res Commun"},{"key":"723_CR162","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1677\/erc.1.00728","volume":"13","author":"KS Kimbro","year":"2006","unstructured":"Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer. 2006;13:739\u201349.","journal-title":"Endocr Relat Cancer"},{"key":"723_CR163","first-page":"2416","volume":"9","author":"NJ Mabjeesh","year":"2003","unstructured":"Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor\/phosphatidylinositol 3\u2019-kinase\/protein kinase B in prostate cancer cells. Clin Cancer Res. 2003;9:2416\u201325.","journal-title":"Clin Cancer Res"},{"key":"723_CR164","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/pros.20473","volume":"67","author":"S Halin","year":"2007","unstructured":"Halin S, Hammarsten P, Wikstrom P, Bergh A. Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. Prostate. 2007;67:370\u20137.","journal-title":"Prostate"},{"key":"723_CR165","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/1097-4644(20010601)81:3<437::AID-JCB1057>3.0.CO;2-6","volume":"81","author":"A Shabsigh","year":"2001","unstructured":"Shabsigh A, Ghafar MA, de la Taille A, Burchardt M, Kaplan SA, Anastasiadis AG, Buttyan R. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem. 2001;81:437\u201344.","journal-title":"J Cell Biochem"},{"key":"723_CR166","doi-asserted-by":"publisher","first-page":"33594","DOI":"10.1074\/jbc.M112.388298","volume":"287","author":"T Mitani","year":"2012","unstructured":"Mitani T, Harada N, Nakano Y, Inui H, Yamaji R. Coordinated action of hypoxia-inducible factor-1alpha and beta-catenin in androgen receptor signaling. J Biol Chem. 2012;287:33594\u2013606.","journal-title":"J Biol Chem"},{"key":"723_CR167","first-page":"45","volume":"22","author":"P Lissoni","year":"2001","unstructured":"Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett. 2001;22:45\u20137.","journal-title":"Neuro Endocrinol Lett"},{"key":"723_CR168","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1600-079X.2012.01030.x","volume":"54","author":"KJ Kim","year":"2013","unstructured":"Kim KJ, Choi JS, Kang I, Kim KW, Jeong CH, Jeong JW. Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model. J Pineal Res. 2013;54:264\u201370.","journal-title":"J Pineal Res"},{"key":"723_CR169","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/jpi.12131","volume":"56","author":"J Leon","year":"2014","unstructured":"Leon J, Casado J, Jimenez Ruiz SM, Zurita MS, Gonzalez-Puga C, Rejon JD, Gila A, Munozde Rueda P, Pavon EJ, Reiter RJ, et al. Melatonin reduces endothelin-1 expression and secretion in colon cancer cells through the inactivation of FoxO-1 and NF-kappabeta. J Pineal Res. 2014;56:415\u201326.","journal-title":"J Pineal Res"},{"key":"723_CR170","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1600-079X.2009.00742.x","volume":"48","author":"SY Park","year":"2010","unstructured":"Park SY, Jang WJ, Yi EY, Jang JY, Jung Y, Jeong JW, Kim YJ. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J Pineal Res. 2010;48:178\u201384.","journal-title":"J Pineal Res"},{"key":"723_CR171","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1600-079X.2009.00678.x","volume":"46","author":"JW Park","year":"2009","unstructured":"Park JW, Hwang MS, Suh SI, Baek WK. Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells. J Pineal Res. 2009;46:415\u201321.","journal-title":"J Pineal Res"},{"key":"723_CR172","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1600-079X.2011.00865.x","volume":"51","author":"SY Cho","year":"2011","unstructured":"Cho SY, Lee HJ, Jeong SJ, Lee HJ, Kim HS, Chen CY, Lee EO, Kim SH. Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1alpha inactivation in hypoxic PC-3 prostate cancer cells. J Pineal Res. 2011;51:87\u201393.","journal-title":"J Pineal Res"},{"key":"723_CR173","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1158\/0008-5472.CAN-09-0389","volume":"69","author":"I Ader","year":"2009","unstructured":"Ader I, Malavaud B, Cuvillier O. When the sphingosine kinase 1\/sphingosine 1-phosphate pathway meets hypoxia signaling: new targets for cancer therapy. Cancer Res. 2009;69:3723\u20136.","journal-title":"Cancer Res"},{"key":"723_CR174","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrclinonc.2011.76","volume":"8","author":"MA Cortez","year":"2011","unstructured":"Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids\u2013the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8:467\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"723_CR175","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.4161\/15384047.2014.955442","volume":"15","author":"SL Romero-Cordoba","year":"2014","unstructured":"Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez-Dorantes M, Hidalgo-Miranda A. miRNA biogenesis: biological impact in the development of cancer. Cancer Biol Ther. 2014;15:1444\u201355.","journal-title":"Cancer Biol Ther"},{"key":"723_CR176","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7150\/jca.9591","volume":"6","author":"EJ Sohn","year":"2015","unstructured":"Sohn EJ, Won G, Lee J, Lee S, Kim SH. Upregulation of miRNA3195 and miRNA374b mediates the anti-angiogenic properties of melatonin in hypoxic PC-3 prostate cancer cells. J Cancer. 2015;6:19\u201328.","journal-title":"J Cancer"},{"key":"723_CR177","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0167-4889(01)00087-8","volume":"1539","author":"S Zelivianski","year":"2001","unstructured":"Zelivianski S, Verni M, Moore C, Kondrikov D, Taylor R, Lin MF. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta. 2001;1539:28\u201343.","journal-title":"Biochim Biophys Acta"},{"key":"723_CR178","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1677\/ERC-07-0061","volume":"14","author":"TC Yuan","year":"2007","unstructured":"Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer. 2007;14:531\u201347.","journal-title":"Endocr Relat Cancer"},{"key":"723_CR179","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/pros.10066","volume":"51","author":"AH Ismail","year":"2002","unstructured":"Ismail AH, Landry F, Aprikian AG, Chevalier S. Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate. Prostate. 2002;51:117\u201325.","journal-title":"Prostate"},{"key":"723_CR180","first-page":"1221","volume":"8","author":"T Ito","year":"2001","unstructured":"Ito T, Yamamoto S, Ohno Y, Namiki K, Aizawa T, Akiyama A, Tachibana M. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. Oncol Rep. 2001;8:1221\u20134.","journal-title":"Oncol Rep"},{"key":"723_CR181","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1073\/pnas.91.12.5330","volume":"91","author":"YJ Bang","year":"1994","unstructured":"Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA. 1994;91:5330\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"723_CR182","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/S0022-5347(05)68241-9","volume":"162","author":"T Burchardt","year":"1999","unstructured":"Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, Hayek O, Dorai T, Buttyan R. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol. 1999;162:1800\u20135.","journal-title":"J Urol"},{"key":"723_CR183","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0022-5347(01)62092-5","volume":"161","author":"HL Adler","year":"1999","unstructured":"Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 1999;161:182\u20137.","journal-title":"J Urol"},{"key":"723_CR184","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H","volume":"41","author":"DE Drachenberg","year":"1999","unstructured":"Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate. 1999;41:127\u201333.","journal-title":"Prostate"},{"key":"723_CR185","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1210\/en.2002-220561","volume":"143","author":"RM Adam","year":"2002","unstructured":"Adam RM, Kim J, Lin J, Orsola A, Zhuang L, Rice DC, Freeman MR. Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology. 2002;143:4599\u2013608.","journal-title":"Endocrinology"},{"key":"723_CR186","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/pros.20173","volume":"63","author":"I Gutierrez-Canas","year":"2005","unstructured":"Gutierrez-Canas I, Juarranz MG, Collado B, Rodriguez-Henche N, Chiloeches A, Prieto JC, Carmena MJ. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. Prostate. 2005;63:44\u201355.","journal-title":"Prostate"},{"key":"723_CR187","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/S0022-5347(01)63837-0","volume":"159","author":"E Gilad","year":"1998","unstructured":"Gilad E, Laudon M, Matzkin H, Zisapel N. Evidence for a local action of melatonin on the rat prostate. J Urol. 1998;159:1069\u201373.","journal-title":"J Urol"},{"key":"723_CR188","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/pros.20155","volume":"63","author":"RM Sainz","year":"2005","unstructured":"Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate. 2005;63:29\u201343.","journal-title":"Prostate"},{"key":"723_CR189","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/jpi.12373","volume":"62","author":"JC Mayo","year":"2017","unstructured":"Mayo JC, Hevia D, Quiros-Gonzalez I, Rodriguez-Garcia A, Gonzalez-Menendez P, Cepas V, Gonzalez-Pola I, Sainz RM. IGFBP3 and MAPK\/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer. J Pineal Res. 2017;62:945.","journal-title":"J Pineal Res"},{"key":"723_CR190","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1600-079X.2012.01017.x","volume":"54","author":"A Rodriguez-Garcia","year":"2013","unstructured":"Rodriguez-Garcia A, Mayo JC, Hevia D, Quiros-Gonzalez I, Navarro M, Sainz RM. Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosis. J Pineal Res. 2013;54:33\u201345.","journal-title":"J Pineal Res"},{"key":"723_CR191","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3389\/fonc.2019.01491","volume":"9","author":"Z Wang","year":"2019","unstructured":"Wang Z, Zhao Y, An Z, Li W. Molecular links between angiogenesis and neuroendocrine phenotypes in prostate cancer progression. Front Oncol. 2019;9:1491.","journal-title":"Front Oncol"},{"key":"723_CR192","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0344-0338(00)80056-4","volume":"196","author":"R Grobholz","year":"2000","unstructured":"Grobholz R, Bohrer MH, Siegsmund M, Junemann KP, Bleyl U, Woenckhaus M. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma. Pathol Res Pract. 2000;196:277\u201384.","journal-title":"Pathol Res Pract"},{"key":"723_CR193","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/35037710","volume":"407","author":"MO Hengartner","year":"2000","unstructured":"Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770\u20136.","journal-title":"Nature"},{"key":"723_CR194","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev.pharmtox.41.1.367","volume":"41","author":"CJ Norbury","year":"2001","unstructured":"Norbury CJ, Hickson ID. Cellular responses to DNA damage. Annu Rev Pharmacol Toxicol. 2001;41:367\u2013401.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"723_CR195","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1126\/science.7878464","volume":"267","author":"CB Thompson","year":"1995","unstructured":"Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456\u201362.","journal-title":"Science"},{"key":"723_CR196","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","volume":"116","author":"NN Danial","year":"2004","unstructured":"Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205\u201319.","journal-title":"Cell"},{"key":"723_CR197","first-page":"222","volume":"18","author":"M Kiedrowski","year":"2014","unstructured":"Kiedrowski M, Mroz A. The effects of selected drugs and dietary compounds on proliferation and apoptosis in colorectal carcinoma. Contemp Oncol (Pozn). 2014;18:222\u20136.","journal-title":"Contemp Oncol (Pozn)"},{"key":"723_CR198","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/35037722","volume":"407","author":"J Savill","year":"2000","unstructured":"Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407:784\u20138.","journal-title":"Nature"},{"key":"723_CR199","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/jpi.12119","volume":"56","author":"Y Hong","year":"2014","unstructured":"Hong Y, Won J, Lee Y, Lee S, Park K, Chang KT, Hong Y. Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells. J Pineal Res. 2014;56:264\u201374.","journal-title":"J Pineal Res"},{"key":"723_CR200","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1600-079X.2009.00682.x","volume":"47","author":"SS Joo","year":"2009","unstructured":"Joo SS, Yoo YM. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res. 2009;47:8\u201314.","journal-title":"J Pineal Res"},{"key":"723_CR201","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1600-079X.2008.00585.x","volume":"45","author":"RM Sainz","year":"2008","unstructured":"Sainz RM, Reiter RJ, Tan DX, Roldan F, Natarajan M, Quiros I, Hevia D, Rodriguez C, Mayo JC. Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro. J Pineal Res. 2008;45:258\u201370.","journal-title":"J Pineal Res"},{"key":"723_CR202","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s11095-016-1901-9","volume":"33","author":"A Flo","year":"2016","unstructured":"Flo A, Calpena AC, Halbaut L, Araya EI, Fernandez F, Clares B. Melatonin delivery: transdermal and transbuccal evaluation in different vehicles. Pharm Res. 2016;33:1615\u201327.","journal-title":"Pharm Res"},{"key":"723_CR203","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/bjc.1995.164","volume":"71","author":"P Lissoni","year":"1995","unstructured":"Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, Tancini G. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer. 1995;71:854\u20136.","journal-title":"Br J Cancer"},{"key":"723_CR204","doi-asserted-by":"publisher","first-page":"e13320","DOI":"10.1111\/and.13320","volume":"51","author":"E Bas","year":"2019","unstructured":"Bas E, Naziroglu M. Treatment with melatonin and selenium attenuates docetaxel-induced apoptosis and oxidative injury in kidney and testes of mice. Andrologia. 2019;51:e13320.","journal-title":"Andrologia"},{"key":"723_CR205","doi-asserted-by":"publisher","first-page":"46768","DOI":"10.18632\/oncotarget.8776","volume":"7","author":"Z Ma","year":"2016","unstructured":"Ma Z, Yang Y, Fan C, Han J, Wang D, Di S, Hu W, Liu D, Li X, Reiter RJ, Yan X. Melatonin as a potential anticarcinogen for non-small-cell lung cancer. Oncotarget. 2016;7:46768\u201384.","journal-title":"Oncotarget"},{"key":"723_CR206","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/jpi.12035","volume":"54","author":"J Wang","year":"2013","unstructured":"Wang J, Guo W, Chen W, Yu W, Tian Y, Fu L, Shi D, Tong B, Xiao X, Huang W, Deng W. Melatonin potentiates the antiproliferative and pro-apoptotic effects of ursolic acid in colon cancer cells by modulating multiple signaling pathways. J Pineal Res. 2013;54:406\u201316.","journal-title":"J Pineal Res"},{"key":"723_CR207","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1211\/002235702760345374","volume":"54","author":"RJ Reiter","year":"2002","unstructured":"Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-Burillo S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol. 2002;54:1299\u2013321.","journal-title":"J Pharm Pharmacol"},{"key":"723_CR208","doi-asserted-by":"publisher","first-page":"5080798","DOI":"10.1155\/2019\/5080798","volume":"2019","author":"GH Tamarindo","year":"2019","unstructured":"Tamarindo GH, Ribeiro DL, Gobbo MG, Guerra LHA, Rahal P, Taboga SR, Gadelha FR, Goes RM. Melatonin and docosahexaenoic acid decrease proliferation of PNT1A prostate benign cells via modulation of mitochondrial bioenergetics and ROS production. Oxid Med Cell Longev. 2019;2019:5080798.","journal-title":"Oxid Med Cell Longev"},{"key":"723_CR209","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/10717544.2017.1338793","volume":"24","author":"L Terraneo","year":"2017","unstructured":"Terraneo L, Bianciardi P, Virgili E, Finati E, Samaja M, Paroni R. Transdermal administration of melatonin coupled to cryopass laser treatment as noninvasive therapy for prostate cancer. Drug Deliv. 2017;24:979\u201385.","journal-title":"Drug Deliv"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-021-00723-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-021-00723-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-021-00723-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T04:45:01Z","timestamp":1675053901000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-021-00723-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":209,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["723"],"URL":"https:\/\/doi.org\/10.1186\/s12964-021-00723-0","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"10 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaraions"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}